Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. Financial performance shows growth, but cash burn and competitive pressures are concerns. The international launch and market expansion are positive, but regulatory and supply chain risks loom. The Q&A reveals some management opacity, particularly around breakeven figures. Without a share repurchase plan and given the lack of strong guidance, the sentiment leans neutral. The absence of market cap data limits the assessment of stock price sensitivity.
Key Financial Performance
Net Product Sales $8.8 million (18% increase year-over-year from $7.4 million in Q1 2024) due to a stronger strategic focus and execution in the market.
Selling and Marketing Expenses $2.9 million (decrease from $5.2 million in Q1 2024) primarily due to the elimination of expenses associated with European pre-commercialization activities.
General and Administrative Expenses $6.1 million (consistent year-over-year with $5.9 million in Q1 2024) increased quarter-over-quarter due to noncash based stock compensation.
Cash and Cash Equivalents $22.6 million as of March 31, 2025, with a cash burn of approximately $4 million in Q1 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launch: PEDMARK has been launched commercially in Germany and the UK following an exclusive licensing agreement with Norgine Pharmaceuticals.
Market Expansion: Fennec is expanding its market reach beyond pediatrics into the adolescent and young adult (AYA) patient population, estimating approximately 20,000 cisplatin chemotherapy patients treated annually in the U.S.
Patient Support Program: Enhancements to the Fennec HEARS patient support program are underway to improve access, streamline reimbursement, and expand home nursing capabilities.
Market Positioning: The market potential in the AYA segment is greater than the pediatric market, with a favorable reimbursement profile via outpatient reimbursement.
International Expansion: PEDMARQSI has been accepted for use in Scotland by the Scottish Medicine Consortium, marking a significant step in expanding access in the EU and UK.
Operational Efficiency: The company recorded net product sales of approximately $8.8 million in Q1 2025, reflecting an 18% growth compared to Q1 2024.
Cost Management: Selling and marketing expenses decreased to $2.9 million in Q1 2025 from $5.2 million in Q1 2024, due to the elimination of European pre-commercialization expenses.
Strategic Focus: Fennec has aligned its organization around clear commercial priorities to enhance field execution and support sustainable growth.
Clinical Engagement: Increased positive engagements with key opinion leaders and strengthened clinical messaging around cisplatin-induced ototoxicity.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Competitive Pressures: Fennec Pharmaceuticals is expanding its market presence beyond pediatrics into the adolescent and young adult (AYA) patient population, which presents both opportunities and competitive pressures as they seek to establish themselves in a larger market.
Regulatory Issues: The company is navigating regulatory landscapes in both the U.S. and Europe, including the acceptance of PEDMARQSI for use in Scotland, which indicates ongoing regulatory challenges in different regions.
Supply Chain Challenges: While the company does not anticipate tariffs impacting their gross margins, the mention of potential tariffs suggests a need for vigilance regarding supply chain costs and their effects on financial performance.
Economic Factors: The company is experiencing cash burn of approximately $4 million in Q1 2025, which raises concerns about financial sustainability and the need for effective cash management as they anticipate higher operating expenses in the first half of the fiscal year.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Targeting Model Development: Fennec implemented a sophisticated targeting model to enhance field execution and engagement, focusing on prescribers treating high numbers of cisplatin patients.
Expansion into AYA Segment: Fennec is expanding its focus beyond pediatrics into the adolescent and young adult (AYA) patient population, estimating approximately 20,000 cisplatin chemotherapy patients treated annually in the U.S.
Fennec HEARS Program Enhancements: The company is enhancing its Fennec HEARS patient support program to improve access, streamline reimbursement, and expand home nursing capabilities.
International Launches: PEDMARK was launched commercially in Germany and the UK, with acceptance for use in Scotland by the Scottish Medicine Consortium.
Investigator-Initiated Trial in Japan: The SDS-J01 trial evaluating PEDMARK in Japan is fully enrolled, with results expected in the second half of 2025.
Net Product Sales Growth: Fennec recorded net product sales of approximately $8.8 million in Q1 2025, reflecting 18% growth year-over-year and anticipating significant growth in the second half of 2025.
Cash Operating Expenses: The company expects full-year cash operating expenses to be approximately $33 million in 2025, similar to 2024.
G&A Expenses: G&A expenses were $6.1 million in Q1 2025, consistent year-over-year, with an increase due to noncash stock compensation.
Cash Burn Rate: Fennec burned approximately $4 million in cash in Q1 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: None
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the average number of vials per patient per full treatment in the AYA space?
A:On average, about 30 vials per patient in the AYA space.
Q:What percentage of patients are making it through the full course of treatment?
A:Around 50% of the patients are getting through full dose or full adherence.
Q:What capabilities in the Fennec HEARS program have driven adherence improvement?
A:Redesigning the program to focus on home administration and ensuring a good experience for patients.
Q:How has the launch with Norgine gone so far?
A:Norgine has launched in the UK and Germany, and we are pleased with the progress and engagement indicators.
Q:Do prescribers know where they land on the tiering algorithm?
A:We don’t typically share that information with our providers.
Q:Is there a revenue number that can lead to breakeven or EPS positive in the second half of the year?
A:We need roughly $8.5 million to $9 million of sales to start generating cash and earnings.
Q:What is the cadence of new country introductions for PEDMARK in Europe?
A:The focus is on the big five in Europe, with Spain, Italy, and France being next up.
Q:Are there any strategic opportunities in oncology supportive care?
A:We are looking at potential synergies and opportunities in supportive care as we grow.
Q:Review of Unclear Management Responses
A:Management did not provide a direct answer regarding whether prescribers know their tiering status, stating they don't typically share that information. Additionally, there was a lack of clarity on the specific revenue number needed for breakeven, as it was mentioned in a general context without specific figures.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AYA treatment
Center New
Children San
City Hope
Comprehensive Health
Consortium SMC
Diego Salt
European Union
Florida Rady
General Hospital
HCPs patient
HEARS healthcare
HEARS patient
Health Center
Hope cancer
Investigator
Member statement
SDS
account
adherence
alignment
care provider
cisplatin
community practice
day today
engagement
expectation
focus
institution community
journey
messaging
model
opinion leader
program
progress area
provider patient
step
tier
FENC Transcript
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
Positive5-14
The earnings call reveals strong financial performance, with a 73% increase in net product sales and positive cash flow. The strategic global expansion and clinical initiatives, coupled with market exclusivity until 2033, further strengthen the outlook. Despite minor concerns about milestone payment uncertainties and operational ramp-up, the positive sentiment is bolstered by optimistic guidance, robust shareholder return plans, and the potential for label expansion through ISTs. The Q&A session supports this sentiment, highlighting growth in demand and strategic targeting of high-volume prescribers.
Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript
Positive3-24
The earnings call summary and Q&A section reveal a positive sentiment. Key highlights include the successful launch of PEDMARK in Europe and the U.K., significant expansion plans, and strong growth trends in the AYA patient segment. The field force expansion and the Fennec HEARS program are expected to drive sales growth. While financial guidance is pending, the anticipated revenue from partnerships and the resolution of litigation issues further bolster the outlook. The absence of unclear management responses also supports a positive sentiment.
Fennec Pharmaceuticals Inc. (FENC) Q2 2025 Earnings Call Transcript
Positive8-19
The earnings call highlights strong financial performance with an 18% sales growth, expansion into new markets, and optimistic future revenue expectations. The Q&A session reveals positive growth in new and repeat customers and strategic market expansion, particularly in the AYA segment, despite some reluctance to share specific numbers. The company's strategy to enhance programs and expand in Europe and Japan indicates a proactive approach, supporting a positive sentiment. However, the lack of specific guidance and royalty impact tempers the outlook slightly, leading to a positive rather than strong positive rating.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call presents mixed signals. Financial performance shows growth, but cash burn and competitive pressures are concerns. The international launch and market expansion are positive, but regulatory and supply chain risks loom. The Q&A reveals some management opacity, particularly around breakeven figures. Without a share repurchase plan and given the lack of strong guidance, the sentiment leans neutral. The absence of market cap data limits the assessment of stock price sensitivity.
FENC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
